PerkinElmer, Inc. (PKI)
| Market Cap | 23.78B |
| Revenue (ttm) | 5.06B |
| Net Income (ttm) | 1.13B |
| Shares Out | 129.81M |
| EPS (ttm) | 10.02 |
| PE Ratio | 18.27 |
| Forward PE | 25.45 |
| Dividend | $0.28 (0.15%) |
| Ex-Dividend Date | Jan 20, 2022 |
| Volume | 1,157,084 |
| Open | 181.31 |
| Previous Close | 179.99 |
| Day's Range | 176.73 - 184.40 |
| 52-Week Range | 119.95 - 192.00 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 188.82 (+3.1%) |
| Earnings Date | Nov 2, 2021 |
About PKI
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, ...
Financial Performance
In 2020, PerkinElmer's revenue was $3.78 billion, an increase of 31.18% compared to the previous year's $2.88 billion. Earnings were $727.89 million, an increase of 219.87%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PerkinElmer stock is "Buy." The 12-month stock price forecast is 188.82, which is an increase of 3.08% from the latest price.
News
PerkinElmer (PKI) Up 6.4% Since Last Earnings Report: Can It Continue?
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?
PerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capability of its RT-PCR Assays
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the performance of its SARS-CoV-2 RT-PCR assays are no...
PerkinElmer Launches Cloud Based Solution to Enable Remote Lab Management
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its PKeye™ Workflow Monitor, a cloud-based platform enabl...
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
PerkinElmer to Present at Evercore ISI HealthCONx Conference 2021
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Evercore ISI 4th Annua...
PerkinElmer to Present at 2021 Stifel Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the virtual 2021 Stifel He...
PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates
PerkinElmer's (PKI) third-quarter results benefit from strong segmental performance.
PerkinElmer Q3 Earnings, FY21 Guidance Beat Wall Street Expectations
PerkinElmer Inc's (NYSE: PKI) Q3 revenues increased 21% Y/Y (12% organic) to $1.17 billion, beating the consensus of $1.04 billion. Diagnostics segment posted $654 million in revenues, +21% (13% organic).
PerkinElmer (PKI) Beats Q3 Earnings and Revenue Estimates
PerkinElmer (PKI) delivered earnings and revenue surprises of 35.88% and 16.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer Announces Financial Results for the Third Quarter of 2021
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the third quarter ended October 3, 202...
Should You Buy PerkinElmer (PKI) Ahead of Earnings?
PerkinElmer (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PerkinElmer Releases 2021 Corporate Social Responsibility Report
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader innovating for a healthier world, today released its 2021 Corporate Social Responsibility (CSR) Report, which summarizes t...
PerkinElmer Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock October 27, 2021. This dividend is paya...
PerkinElmer (PKI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at the Diagnostics segment.
PerkinElmer and International Society for Neonatal Screening Host Virtual Summit to Discuss Implementation of India's...
DELHI, India--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, joined forces with the International Society for Neonatal Screening (ISNS) to host the In...
PerkinElmer Signals Research Suite Platform Integrates Scientific Data Silos and Enhances Collaboration for R&D Teams
WALTHAM, Mass.--(BUSINESS WIRE)--Signals Research™ Suite provides secure, SaaS platform helping pharma and industrial R&D teams make more efficient & effective data-driven decisions.
PerkinElmer (PKI) Sees Hammer Chart Pattern: Time to Buy?
PerkinElmer (PKI) has been struggling lately, but the selling pressure may be coming to an end soon.
Which Stocks Are More Attractive Than eBay's Stock?
We believe that there are other stocks that are currently better valued than eBay's stock. EBAY's current price-to-operating income ratio (P/EBIT) of 16.7x is higher than levels of 13.3x for PerkinElmer...
PKI or MTD: Which Is the Better Value Stock Right Now?
PKI vs. MTD: Which Stock Is the Better Value Option?
Will PerkinElmer (PKI) Beat Estimates Again in Its Next Earnings Report?
PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Looking for Earnings Beat? Play These 5 Stocks
Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.
PerkinElmer's (PKI) New Deal to Improve Single-Cell Profiling
PerkinElmer (PKI) partners with Honeycomb Biotechnologies to launch HIVE scRNAseq Solution, which can advance single-cell profiling.
PerkinElmer and Honeycomb Biotechnologies Launch the HIVE scRNAseq Solution for Single-Cell Analysis
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer and Honeycomb Biotechnologies, Inc., have launched the first of its kind HIVE scRNAseq Solution for single-cell isolation and analysis.